Table 3. Overall survival benefit of adjuvant chemotherapy.

Trial	Patients n	Stage	5-year survival benefit, %	Hazard ratio (95% CI)	p-value
ALPI	1209	I–IIIA	3	0.96 (0.81–1.13)	0.589
IALT	1867	I–IIIA	4	0.91 (0.81–1.02)	0.03
BLT	381	I–IIIA	2	1.02 (0.77–1.35)	0.90
BR10	482	IB–II	15	0.69 (0.52–0.91)	0.04
ANITA	840	IB–IIIA	9	0.8 (0.66–0.96)	0.017
LACE	4584	I–IIIA	5	0.89 (0.82–0.96)	0.004
IGR-MRC	8147	I–IIIA	4	-0.87 (0.81–0.93)	<0.0000001

Reproduced from [3] with permission from the publisher.